| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 118 | 2024 | 923 | 12.090 |
Why?
|
| Immunotherapy, Adoptive | 40 | 2025 | 254 | 8.650 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 23 | 2025 | 187 | 5.610 |
Why?
|
| Hematologic Neoplasms | 32 | 2024 | 355 | 5.020 |
Why?
|
| Transplantation Conditioning | 45 | 2024 | 380 | 4.460 |
Why?
|
| Graft vs Host Disease | 48 | 2024 | 366 | 3.910 |
Why?
|
| Transplantation, Homologous | 79 | 2024 | 1015 | 3.180 |
Why?
|
| Lymphoma, Non-Hodgkin | 19 | 2023 | 268 | 3.160 |
Why?
|
| Receptors, Antigen, T-Cell | 13 | 2024 | 419 | 2.960 |
Why?
|
| Lymphoma | 12 | 2020 | 267 | 2.260 |
Why?
|
| Multiple Myeloma | 15 | 2023 | 342 | 1.910 |
Why?
|
| Leukemia, Myeloid, Acute | 19 | 2021 | 815 | 1.900 |
Why?
|
| T-Lymphocytes | 22 | 2021 | 1277 | 1.850 |
Why?
|
| Graft vs Tumor Effect | 14 | 2015 | 26 | 1.820 |
Why?
|
| Lymphoma, B-Cell | 5 | 2022 | 109 | 1.670 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2025 | 61 | 1.520 |
Why?
|
| Antigens, CD19 | 16 | 2025 | 69 | 1.450 |
Why?
|
| Humans | 211 | 2025 | 92337 | 1.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 26 | 2023 | 2556 | 1.430 |
Why?
|
| Transplantation, Autologous | 22 | 2021 | 355 | 1.380 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2023 | 407 | 1.370 |
Why?
|
| Leukemia | 11 | 2022 | 321 | 1.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 12 | 2022 | 164 | 1.300 |
Why?
|
| Bone Marrow Transplantation | 19 | 2019 | 289 | 1.240 |
Why?
|
| Salvage Therapy | 6 | 2021 | 234 | 1.230 |
Why?
|
| Lymphocyte Transfusion | 7 | 2013 | 40 | 1.180 |
Why?
|
| Immunotherapy | 8 | 2022 | 725 | 1.150 |
Why?
|
| Hodgkin Disease | 10 | 2023 | 170 | 1.100 |
Why?
|
| Stem Cell Transplantation | 10 | 2020 | 190 | 1.090 |
Why?
|
| Adult | 102 | 2025 | 27532 | 1.080 |
Why?
|
| Recurrence | 26 | 2025 | 1180 | 1.050 |
Why?
|
| Myelodysplastic Syndromes | 14 | 2020 | 368 | 1.040 |
Why?
|
| Middle Aged | 92 | 2025 | 27030 | 0.990 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2023 | 28 | 0.940 |
Why?
|
| Male | 98 | 2025 | 43925 | 0.940 |
Why?
|
| Female | 107 | 2025 | 47893 | 0.930 |
Why?
|
| Aged | 59 | 2025 | 19943 | 0.910 |
Why?
|
| Lymphocyte Depletion | 8 | 2017 | 99 | 0.900 |
Why?
|
| Transplantation Chimera | 7 | 2015 | 84 | 0.860 |
Why?
|
| Oncologists | 1 | 2024 | 38 | 0.850 |
Why?
|
| Neoplasm Recurrence, Local | 16 | 2025 | 1398 | 0.770 |
Why?
|
| Treatment Outcome | 44 | 2025 | 8740 | 0.770 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2020 | 461 | 0.770 |
Why?
|
| Transplants | 1 | 2022 | 43 | 0.750 |
Why?
|
| Blood Component Removal | 2 | 2020 | 26 | 0.720 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2020 | 318 | 0.720 |
Why?
|
| Graft Survival | 10 | 2016 | 935 | 0.720 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 328 | 0.710 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 313 | 0.710 |
Why?
|
| Tissue Donors | 10 | 2022 | 531 | 0.710 |
Why?
|
| Jehovah's Witnesses | 1 | 2021 | 21 | 0.700 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 162 | 0.690 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 10 | 2008 | 167 | 0.680 |
Why?
|
| Tumor Lysis Syndrome | 4 | 2013 | 11 | 0.680 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2024 | 215 | 0.670 |
Why?
|
| Myeloablative Agonists | 4 | 2019 | 36 | 0.660 |
Why?
|
| Monitoring, Physiologic | 2 | 2012 | 267 | 0.660 |
Why?
|
| Lymphoma, Follicular | 3 | 2019 | 74 | 0.650 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 7 | 2015 | 66 | 0.640 |
Why?
|
| Remission Induction | 15 | 2025 | 763 | 0.620 |
Why?
|
| Geriatric Assessment | 5 | 2024 | 186 | 0.600 |
Why?
|
| Clinical Trials as Topic | 11 | 2022 | 1150 | 0.600 |
Why?
|
| Antigens, Neoplasm | 4 | 2018 | 345 | 0.580 |
Why?
|
| Cell- and Tissue-Based Therapy | 7 | 2024 | 58 | 0.580 |
Why?
|
| Betacoronavirus | 2 | 2020 | 269 | 0.580 |
Why?
|
| Combined Modality Therapy | 17 | 2024 | 1733 | 0.570 |
Why?
|
| Breast Neoplasms | 10 | 2011 | 3053 | 0.560 |
Why?
|
| Hematopoietic Stem Cells | 7 | 2019 | 310 | 0.560 |
Why?
|
| Lymphoma, T-Cell | 2 | 2016 | 59 | 0.550 |
Why?
|
| Cord Blood Stem Cell Transplantation | 5 | 2019 | 91 | 0.520 |
Why?
|
| Retrospective Studies | 34 | 2025 | 9703 | 0.520 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2016 | 5 | 0.510 |
Why?
|
| Neoplasms | 7 | 2022 | 3117 | 0.500 |
Why?
|
| Disease-Free Survival | 18 | 2021 | 1181 | 0.490 |
Why?
|
| Antineoplastic Agents | 14 | 2018 | 2368 | 0.480 |
Why?
|
| Biological Products | 5 | 2025 | 171 | 0.460 |
Why?
|
| Cytokines | 6 | 2021 | 843 | 0.460 |
Why?
|
| Immunosuppressive Agents | 8 | 2024 | 989 | 0.450 |
Why?
|
| Th2 Cells | 4 | 2013 | 148 | 0.450 |
Why?
|
| Adolescent | 32 | 2025 | 9504 | 0.450 |
Why?
|
| Cyclophosphamide | 10 | 2023 | 304 | 0.440 |
Why?
|
| Rituximab | 5 | 2019 | 123 | 0.420 |
Why?
|
| Adoptive Transfer | 2 | 2004 | 173 | 0.420 |
Why?
|
| Sirolimus | 4 | 2024 | 174 | 0.420 |
Why?
|
| Young Adult | 22 | 2025 | 6624 | 0.400 |
Why?
|
| Interleukin-7 | 2 | 2012 | 47 | 0.400 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 149 | 0.390 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 1919 | 0.390 |
Why?
|
| Survival Rate | 17 | 2025 | 1927 | 0.380 |
Why?
|
| Neoplasm, Residual | 7 | 2024 | 188 | 0.380 |
Why?
|
| Immunization | 1 | 2012 | 163 | 0.380 |
Why?
|
| Education | 2 | 2011 | 58 | 0.370 |
Why?
|
| Survival Analysis | 17 | 2021 | 1511 | 0.360 |
Why?
|
| Chronic Disease | 11 | 2024 | 963 | 0.350 |
Why?
|
| Congresses as Topic | 2 | 2018 | 120 | 0.350 |
Why?
|
| Etoposide | 8 | 2019 | 206 | 0.350 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2022 | 183 | 0.340 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 4 | 2000 | 15 | 0.340 |
Why?
|
| Antibodies, Monoclonal | 4 | 2017 | 1399 | 0.330 |
Why?
|
| Thionucleotides | 4 | 2000 | 55 | 0.330 |
Why?
|
| Pandemics | 3 | 2020 | 812 | 0.330 |
Why?
|
| Vincristine | 5 | 2019 | 109 | 0.330 |
Why?
|
| HLA Antigens | 6 | 2016 | 227 | 0.320 |
Why?
|
| Hematopoiesis | 5 | 2019 | 172 | 0.320 |
Why?
|
| United States | 16 | 2024 | 7348 | 0.310 |
Why?
|
| Doxorubicin | 5 | 2019 | 296 | 0.300 |
Why?
|
| National Cancer Institute (U.S.) | 7 | 2013 | 72 | 0.300 |
Why?
|
| Oligonucleotides, Antisense | 3 | 1997 | 67 | 0.290 |
Why?
|
| Prednisone | 4 | 2019 | 254 | 0.290 |
Why?
|
| Alemtuzumab | 2 | 2024 | 90 | 0.290 |
Why?
|
| Vidarabine | 5 | 2019 | 144 | 0.280 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2012 | 79 | 0.280 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2025 | 624 | 0.280 |
Why?
|
| Prospective Studies | 12 | 2023 | 4468 | 0.270 |
Why?
|
| Prognosis | 12 | 2025 | 3872 | 0.270 |
Why?
|
| Graft Rejection | 5 | 2016 | 1110 | 0.270 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2013 | 11 | 0.260 |
Why?
|
| Secondary Prevention | 7 | 2013 | 172 | 0.260 |
Why?
|
| Interleukin-4 | 1 | 2006 | 131 | 0.260 |
Why?
|
| Immunomodulation | 2 | 2018 | 62 | 0.250 |
Why?
|
| Transplantation Immunology | 5 | 2013 | 83 | 0.250 |
Why?
|
| Methotrexate | 2 | 2024 | 245 | 0.250 |
Why?
|
| Tacrolimus | 2 | 2024 | 373 | 0.240 |
Why?
|
| Child, Preschool | 10 | 2016 | 3818 | 0.240 |
Why?
|
| Quality of Life | 4 | 2020 | 1744 | 0.240 |
Why?
|
| Autocrine Communication | 1 | 2024 | 21 | 0.230 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2010 | 174 | 0.220 |
Why?
|
| Time Factors | 9 | 2021 | 5430 | 0.210 |
Why?
|
| Cyclosporine | 1 | 2024 | 241 | 0.210 |
Why?
|
| Disease Management | 3 | 2019 | 340 | 0.210 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2020 | 214 | 0.210 |
Why?
|
| Cyclic AMP | 1 | 2024 | 280 | 0.210 |
Why?
|
| Registries | 2 | 2007 | 902 | 0.210 |
Why?
|
| Oligopeptides | 1 | 2024 | 190 | 0.210 |
Why?
|
| Immunologic Factors | 2 | 2022 | 175 | 0.200 |
Why?
|
| Child | 13 | 2016 | 7334 | 0.200 |
Why?
|
| Histocompatibility Testing | 5 | 2017 | 138 | 0.200 |
Why?
|
| Whole-Body Irradiation | 5 | 2019 | 68 | 0.190 |
Why?
|
| Fetal Blood | 3 | 2017 | 93 | 0.190 |
Why?
|
| Flow Cytometry | 5 | 2012 | 704 | 0.190 |
Why?
|
| Bone Marrow Purging | 3 | 2002 | 7 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 2 | 2007 | 245 | 0.190 |
Why?
|
| Unrelated Donors | 3 | 2017 | 46 | 0.190 |
Why?
|
| Immunophenotyping | 5 | 2016 | 222 | 0.180 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2022 | 154 | 0.180 |
Why?
|
| Acute Coronary Syndrome | 1 | 2022 | 35 | 0.180 |
Why?
|
| Neoplasm Staging | 6 | 2016 | 2035 | 0.180 |
Why?
|
| Risk Factors | 10 | 2018 | 5704 | 0.180 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 22 | 0.180 |
Why?
|
| Cardiology | 1 | 2022 | 123 | 0.170 |
Why?
|
| Leukocyte Transfusion | 1 | 2000 | 15 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 598 | 0.170 |
Why?
|
| Animals | 13 | 2024 | 28003 | 0.170 |
Why?
|
| Haplotypes | 3 | 2019 | 639 | 0.170 |
Why?
|
| CD3 Complex | 3 | 2013 | 136 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 2 | 2022 | 490 | 0.170 |
Why?
|
| Blood Pressure | 1 | 2024 | 909 | 0.170 |
Why?
|
| Lymphocytes | 2 | 2023 | 476 | 0.170 |
Why?
|
| Glucocorticoids | 2 | 2015 | 367 | 0.160 |
Why?
|
| Antigens, CD34 | 5 | 2017 | 161 | 0.160 |
Why?
|
| Carcinoma | 1 | 2023 | 438 | 0.160 |
Why?
|
| Automobiles | 1 | 2019 | 14 | 0.160 |
Why?
|
| HLA-A24 Antigen | 1 | 2019 | 20 | 0.160 |
Why?
|
| Melanoma | 1 | 2024 | 482 | 0.160 |
Why?
|
| Interleukin-15 | 2 | 2012 | 76 | 0.160 |
Why?
|
| Plasma Exchange | 1 | 2019 | 26 | 0.160 |
Why?
|
| Cell Differentiation | 2 | 2025 | 1592 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 866 | 0.160 |
Why?
|
| ABO Blood-Group System | 1 | 2019 | 59 | 0.160 |
Why?
|
| Paraproteinemias | 1 | 2019 | 17 | 0.160 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 6916 | 0.160 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 131 | 0.150 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 59 | 0.150 |
Why?
|
| Cognition | 2 | 2021 | 603 | 0.150 |
Why?
|
| Blood Donors | 2 | 2015 | 23 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 205 | 0.150 |
Why?
|
| Isoantibodies | 1 | 2019 | 122 | 0.150 |
Why?
|
| Genetic Engineering | 1 | 2018 | 117 | 0.150 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 786 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 3775 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 139 | 0.150 |
Why?
|
| Killer Cells, Natural | 5 | 2011 | 277 | 0.150 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 1763 | 0.140 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 298 | 0.140 |
Why?
|
| Mitoxantrone | 1 | 2018 | 68 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 209 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 2 | 2011 | 172 | 0.140 |
Why?
|
| Preoperative Care | 1 | 2019 | 406 | 0.140 |
Why?
|
| Cytarabine | 1 | 2018 | 222 | 0.140 |
Why?
|
| Power Plants | 1 | 1997 | 5 | 0.140 |
Why?
|
| Radioactive Hazard Release | 1 | 1997 | 8 | 0.140 |
Why?
|
| Cause of Death | 4 | 2018 | 270 | 0.140 |
Why?
|
| Roseolovirus Infections | 2 | 2006 | 9 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2019 | 295 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2024 | 3508 | 0.130 |
Why?
|
| Survivors | 3 | 2013 | 199 | 0.130 |
Why?
|
| Herpesvirus 6, Human | 2 | 2006 | 21 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 1079 | 0.130 |
Why?
|
| Fractures, Spontaneous | 1 | 2016 | 14 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2008 | 70 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 333 | 0.130 |
Why?
|
| Bone Neoplasms | 2 | 2016 | 313 | 0.130 |
Why?
|
| Acute Disease | 4 | 2013 | 856 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2019 | 322 | 0.130 |
Why?
|
| Neoplasm Metastasis | 4 | 2015 | 1071 | 0.130 |
Why?
|
| Haploidy | 1 | 2016 | 32 | 0.130 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 9 | 0.130 |
Why?
|
| Anthracyclines | 1 | 2016 | 35 | 0.130 |
Why?
|
| Gene Expression | 1 | 2020 | 1312 | 0.130 |
Why?
|
| Echocardiography | 1 | 2021 | 968 | 0.130 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2011 | 109 | 0.130 |
Why?
|
| Biomarkers | 4 | 2022 | 1850 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 1997 | 158 | 0.120 |
Why?
|
| Osteosarcoma | 1 | 2016 | 159 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 65 | 0.120 |
Why?
|
| Nausea | 2 | 2012 | 179 | 0.120 |
Why?
|
| Brain Diseases | 2 | 2006 | 186 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 680 | 0.120 |
Why?
|
| Vomiting | 2 | 2012 | 199 | 0.120 |
Why?
|
| Preoperative Period | 2 | 2018 | 98 | 0.120 |
Why?
|
| Donor Selection | 1 | 2015 | 79 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 100 | 0.120 |
Why?
|
| Cohort Studies | 9 | 2014 | 2978 | 0.120 |
Why?
|
| Fractures, Bone | 1 | 2016 | 146 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 111 | 0.120 |
Why?
|
| Medical Oncology | 2 | 2009 | 393 | 0.120 |
Why?
|
| Abdominal Neoplasms | 1 | 2014 | 40 | 0.120 |
Why?
|
| Pilot Projects | 4 | 2020 | 900 | 0.110 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 1247 | 0.110 |
Why?
|
| Trastuzumab | 2 | 2006 | 78 | 0.110 |
Why?
|
| Judgment | 1 | 2015 | 68 | 0.110 |
Why?
|
| Comorbidity | 3 | 2018 | 987 | 0.110 |
Why?
|
| Forecasting | 1 | 2015 | 311 | 0.110 |
Why?
|
| Infant | 5 | 2014 | 3218 | 0.110 |
Why?
|
| Melphalan | 3 | 2023 | 100 | 0.110 |
Why?
|
| Blood Preservation | 1 | 2013 | 11 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 291 | 0.110 |
Why?
|
| Consensus | 1 | 2015 | 376 | 0.110 |
Why?
|
| Bone Marrow | 3 | 2012 | 445 | 0.110 |
Why?
|
| Disease Progression | 5 | 2016 | 1503 | 0.110 |
Why?
|
| Immunologic Memory | 2 | 2006 | 177 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2022 | 429 | 0.110 |
Why?
|
| Vena Cava, Inferior | 1 | 2014 | 140 | 0.110 |
Why?
|
| Cryopreservation | 1 | 2013 | 72 | 0.100 |
Why?
|
| Immunity, Cellular | 2 | 2012 | 182 | 0.100 |
Why?
|
| Transplantation, Haploidentical | 3 | 2017 | 28 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 977 | 0.100 |
Why?
|
| Biopsy | 2 | 2019 | 1194 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2000 | 112 | 0.100 |
Why?
|
| Neutropenia | 2 | 2012 | 217 | 0.100 |
Why?
|
| Neutrophils | 3 | 2019 | 323 | 0.100 |
Why?
|
| Thrombectomy | 1 | 2014 | 197 | 0.100 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2012 | 12 | 0.100 |
Why?
|
| Hemocyanins | 1 | 2012 | 8 | 0.100 |
Why?
|
| Health Status | 2 | 2013 | 376 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2016 | 438 | 0.100 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2012 | 6 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2013 | 235 | 0.100 |
Why?
|
| Australia | 2 | 2023 | 102 | 0.100 |
Why?
|
| Recombinant Proteins | 4 | 2008 | 1016 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2014 | 253 | 0.100 |
Why?
|
| Spinal Puncture | 1 | 2012 | 39 | 0.100 |
Why?
|
| Th1 Cells | 1 | 2013 | 168 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 2009 | 0.090 |
Why?
|
| Epitopes | 1 | 2012 | 249 | 0.090 |
Why?
|
| Chimerism | 3 | 2020 | 37 | 0.090 |
Why?
|
| Heart Failure | 1 | 2022 | 1346 | 0.090 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2012 | 111 | 0.090 |
Why?
|
| Constipation | 1 | 2012 | 69 | 0.090 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 82 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 115 | 0.090 |
Why?
|
| Allografts | 3 | 2019 | 197 | 0.090 |
Why?
|
| Sickness Impact Profile | 2 | 2011 | 26 | 0.090 |
Why?
|
| Recovery of Function | 2 | 2019 | 317 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 288 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 698 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2011 | 55 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2013 | 329 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 1 | 2012 | 183 | 0.090 |
Why?
|
| Herpesvirus 4, Human | 1 | 2011 | 122 | 0.090 |
Why?
|
| Filgrastim | 2 | 2000 | 58 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2011 | 169 | 0.080 |
Why?
|
| Group Processes | 1 | 2010 | 31 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 341 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 2 | 2009 | 85 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2008 | 2369 | 0.080 |
Why?
|
| B-Lymphocytes | 3 | 2011 | 754 | 0.080 |
Why?
|
| Sarcoma | 1 | 2011 | 216 | 0.080 |
Why?
|
| Prednisolone | 2 | 2012 | 41 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 868 | 0.080 |
Why?
|
| Peptide Library | 1 | 2009 | 84 | 0.080 |
Why?
|
| Thiazoles | 1 | 2010 | 128 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2013 | 391 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2008 | 731 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2010 | 311 | 0.080 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 1576 | 0.080 |
Why?
|
| CD8 Antigens | 1 | 2008 | 81 | 0.080 |
Why?
|
| Risk | 3 | 2011 | 661 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2011 | 265 | 0.080 |
Why?
|
| Living Donors | 2 | 2008 | 342 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2009 | 871 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2011 | 2458 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2008 | 51 | 0.070 |
Why?
|
| Siblings | 1 | 2008 | 108 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2009 | 145 | 0.070 |
Why?
|
| Mice | 6 | 2024 | 12110 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2012 | 552 | 0.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2010 | 139 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2016 | 225 | 0.070 |
Why?
|
| Vulvovaginitis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Lymphocytosis | 1 | 2007 | 13 | 0.070 |
Why?
|
| Infusions, Intravenous | 3 | 2024 | 416 | 0.070 |
Why?
|
| Bioethical Issues | 1 | 2007 | 38 | 0.070 |
Why?
|
| Smoking | 1 | 2011 | 640 | 0.070 |
Why?
|
| Receptors, Immunologic | 1 | 2008 | 142 | 0.070 |
Why?
|
| Allopurinol | 2 | 2004 | 78 | 0.070 |
Why?
|
| Lymphocyte Count | 1 | 2007 | 100 | 0.070 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2007 | 5 | 0.070 |
Why?
|
| Cell Survival | 3 | 2013 | 1008 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2010 | 378 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1477 | 0.070 |
Why?
|
| Japan | 2 | 2021 | 306 | 0.070 |
Why?
|
| Estrogens | 1 | 2007 | 200 | 0.070 |
Why?
|
| Immunotoxins | 1 | 2006 | 15 | 0.060 |
Why?
|
| Intestinal Neoplasms | 1 | 2007 | 69 | 0.060 |
Why?
|
| Aminoglycosides | 1 | 2006 | 33 | 0.060 |
Why?
|
| Histocompatibility | 3 | 2016 | 66 | 0.060 |
Why?
|
| Stem Cells | 1 | 2009 | 383 | 0.060 |
Why?
|
| PUVA Therapy | 1 | 2006 | 24 | 0.060 |
Why?
|
| Death | 1 | 2006 | 92 | 0.060 |
Why?
|
| Saliva | 1 | 2007 | 126 | 0.060 |
Why?
|
| Cetuximab | 1 | 2006 | 114 | 0.060 |
Why?
|
| Proteome | 1 | 2007 | 149 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2025 | 622 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2006 | 270 | 0.060 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2004 | 15 | 0.060 |
Why?
|
| Receptors, Neuropeptide | 1 | 2024 | 9 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 4 | 2011 | 923 | 0.060 |
Why?
|
| Emergency Service, Hospital | 1 | 2009 | 559 | 0.060 |
Why?
|
| Conjunctivitis | 1 | 2004 | 7 | 0.060 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2024 | 34 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 569 | 0.060 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2024 | 61 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2004 | 72 | 0.050 |
Why?
|
| Immunoglobulin A | 2 | 2019 | 87 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 165 | 0.050 |
Why?
|
| Cicatrix | 1 | 2004 | 71 | 0.050 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2004 | 39 | 0.050 |
Why?
|
| Incidence | 5 | 2015 | 1661 | 0.050 |
Why?
|
| DNA, Viral | 3 | 2011 | 253 | 0.050 |
Why?
|
| Inflammation | 1 | 2009 | 1025 | 0.050 |
Why?
|
| Hippocampus | 1 | 2006 | 435 | 0.050 |
Why?
|
| Placebos | 2 | 2000 | 211 | 0.050 |
Why?
|
| Urate Oxidase | 1 | 2003 | 11 | 0.050 |
Why?
|
| Historically Controlled Study | 1 | 2022 | 6 | 0.050 |
Why?
|
| RNA, Viral | 3 | 2011 | 301 | 0.050 |
Why?
|
| Vaccination | 1 | 2005 | 285 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 282 | 0.050 |
Why?
|
| Hyperuricemia | 1 | 2003 | 24 | 0.050 |
Why?
|
| Monocytes | 1 | 2004 | 223 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 142 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 106 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2004 | 278 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2003 | 1756 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2023 | 314 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2680 | 0.050 |
Why?
|
| Checklist | 1 | 2022 | 68 | 0.050 |
Why?
|
| Models, Biological | 1 | 2009 | 1786 | 0.050 |
Why?
|
| Idarubicin | 1 | 2001 | 8 | 0.050 |
Why?
|
| Histiocytes | 1 | 2021 | 23 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2015 | 283 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 318 | 0.050 |
Why?
|
| Blood Cell Count | 2 | 2013 | 80 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2002 | 299 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2001 | 125 | 0.050 |
Why?
|
| Ligands | 1 | 2022 | 457 | 0.040 |
Why?
|
| North America | 1 | 2021 | 188 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2001 | 109 | 0.040 |
Why?
|
| Atrial Function, Left | 1 | 2021 | 53 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 286 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 112 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 328 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 162 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 709 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2000 | 71 | 0.040 |
Why?
|
| Platelet Count | 1 | 2000 | 92 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2003 | 473 | 0.040 |
Why?
|
| Hydrazines | 1 | 2020 | 32 | 0.040 |
Why?
|
| Cell Movement | 1 | 2004 | 797 | 0.040 |
Why?
|
| Executive Function | 1 | 2021 | 99 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1939 | 0.040 |
Why?
|
| Iron Chelating Agents | 1 | 2000 | 4 | 0.040 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 22 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 51 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2006 | 2517 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 201 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 252 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2022 | 462 | 0.040 |
Why?
|
| Patient Selection | 2 | 2019 | 689 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 84 | 0.040 |
Why?
|
| Triazoles | 1 | 2020 | 108 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 59 | 0.040 |
Why?
|
| Heart Atria | 1 | 2021 | 289 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2000 | 476 | 0.040 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 10 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 68 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 523 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2019 | 85 | 0.040 |
Why?
|
| Iron | 1 | 2000 | 174 | 0.040 |
Why?
|
| Aspergillus | 1 | 1998 | 9 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 1905 | 0.040 |
Why?
|
| Kidney | 1 | 2024 | 1145 | 0.040 |
Why?
|
| Gastroparesis | 1 | 1998 | 14 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 117 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2019 | 79 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 69 | 0.040 |
Why?
|
| Aspergillosis | 1 | 1998 | 39 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 86 | 0.040 |
Why?
|
| Germany | 1 | 2018 | 74 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 268 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2011 | 130 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2019 | 262 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 259 | 0.040 |
Why?
|
| Premedication | 1 | 2017 | 57 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 263 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 373 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 291 | 0.030 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1997 | 11 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 390 | 0.030 |
Why?
|
| Ukraine | 1 | 1997 | 20 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 3360 | 0.030 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 1996 | 7 | 0.030 |
Why?
|
| Blast Crisis | 1 | 1996 | 37 | 0.030 |
Why?
|
| Limb Salvage | 1 | 2016 | 38 | 0.030 |
Why?
|
| Parkinson Disease, Secondary | 1 | 1996 | 4 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 800 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 1142 | 0.030 |
Why?
|
| Brain | 1 | 2006 | 2352 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 652 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 36 | 0.030 |
Why?
|
| Pentostatin | 1 | 2015 | 30 | 0.030 |
Why?
|
| Rabbits | 1 | 1996 | 644 | 0.030 |
Why?
|
| Complementarity Determining Regions | 1 | 2015 | 25 | 0.030 |
Why?
|
| Time | 1 | 2015 | 79 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1720 | 0.030 |
Why?
|
| Hepatoblastoma | 1 | 2014 | 13 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 150 | 0.030 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2014 | 15 | 0.030 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2014 | 21 | 0.030 |
Why?
|
| Wilms Tumor | 1 | 2014 | 37 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 337 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 152 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1294 | 0.030 |
Why?
|
| Probability | 1 | 2015 | 357 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2015 | 161 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3017 | 0.030 |
Why?
|
| Blood Specimen Collection | 1 | 2013 | 28 | 0.030 |
Why?
|
| Environment | 1 | 2015 | 229 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 85 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 785 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 1807 | 0.020 |
Why?
|
| Cell Division | 3 | 2001 | 701 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2006 | 207 | 0.020 |
Why?
|
| Mental Health | 1 | 2013 | 184 | 0.020 |
Why?
|
| Motivation | 1 | 2015 | 310 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 3 | 2001 | 1052 | 0.020 |
Why?
|
| Sarcoma, Ewing | 1 | 2012 | 43 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 22 | 0.020 |
Why?
|
| Learning | 1 | 2015 | 295 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 559 | 0.020 |
Why?
|
| Data Collection | 1 | 2013 | 379 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 343 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2011 | 47 | 0.020 |
Why?
|
| Hematology | 1 | 2011 | 30 | 0.020 |
Why?
|
| Mitogens | 2 | 2003 | 61 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2011 | 126 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2010 | 1310 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 2010 | 73 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 996 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1119 | 0.020 |
Why?
|
| Pneumonia | 1 | 2011 | 189 | 0.020 |
Why?
|
| Dasatinib | 1 | 2010 | 38 | 0.020 |
Why?
|
| Sclerosis | 1 | 2010 | 29 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2010 | 72 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 289 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 530 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 224 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 174 | 0.020 |
Why?
|
| Data Mining | 1 | 2009 | 44 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2011 | 444 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2009 | 84 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 2498 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2010 | 218 | 0.020 |
Why?
|
| Leukapheresis | 1 | 2008 | 20 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 767 | 0.020 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 167 | 0.020 |
Why?
|
| CD56 Antigen | 1 | 2008 | 18 | 0.020 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2008 | 20 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 402 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2008 | 33 | 0.020 |
Why?
|
| Contraindications | 1 | 2007 | 70 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2007 | 97 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2006 | 2037 | 0.020 |
Why?
|
| Primary Myelofibrosis | 1 | 2008 | 67 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 891 | 0.020 |
Why?
|
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2007 | 5 | 0.020 |
Why?
|
| Lactoferrin | 1 | 2007 | 10 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 27 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 2007 | 24 | 0.020 |
Why?
|
| Truth Disclosure | 1 | 2007 | 92 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2007 | 79 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2006 | 133 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 456 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2007 | 105 | 0.020 |
Why?
|
| Astrocytes | 1 | 2006 | 143 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2006 | 18 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2074 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2010 | 404 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 538 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2004 | 1902 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2006 | 286 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 485 | 0.010 |
Why?
|
| Bone Marrow Cells | 2 | 1998 | 264 | 0.010 |
Why?
|
| Receptors, CCR7 | 1 | 2004 | 17 | 0.010 |
Why?
|
| L-Selectin | 1 | 2004 | 17 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 31 | 0.010 |
Why?
|
| Celiac Disease | 1 | 2007 | 216 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 874 | 0.010 |
Why?
|
| Antimetabolites | 1 | 2003 | 24 | 0.010 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 2003 | 27 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 200 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 2729 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 2902 | 0.010 |
Why?
|
| Cell Count | 1 | 2003 | 200 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2003 | 139 | 0.010 |
Why?
|
| Life Tables | 1 | 2002 | 47 | 0.010 |
Why?
|
| Skin | 1 | 2005 | 594 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 145 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2001 | 312 | 0.010 |
Why?
|
| Biological Transport | 1 | 2001 | 410 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 542 | 0.010 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2000 | 12 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 2000 | 22 | 0.010 |
Why?
|
| Cadmium | 1 | 2000 | 28 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2000 | 171 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2000 | 118 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2000 | 68 | 0.010 |
Why?
|
| Copper | 1 | 2000 | 78 | 0.010 |
Why?
|
| Zinc | 1 | 2000 | 100 | 0.010 |
Why?
|
| Erythromycin | 1 | 1998 | 10 | 0.010 |
Why?
|
| Gastric Emptying | 1 | 1998 | 25 | 0.010 |
Why?
|
| Toxicity Tests | 1 | 1998 | 13 | 0.010 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 1998 | 8 | 0.010 |
Why?
|
| K562 Cells | 1 | 1998 | 47 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 1550 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1998 | 94 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1998 | 150 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 1998 | 176 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2000 | 306 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1998 | 265 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1998 | 398 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1998 | 167 | 0.010 |
Why?
|
| Gastrointestinal Agents | 1 | 1998 | 179 | 0.010 |
Why?
|
| Haloperidol | 1 | 1996 | 29 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2000 | 887 | 0.010 |
Why?
|
| Levodopa | 1 | 1996 | 38 | 0.010 |
Why?
|
| Carmustine | 1 | 1996 | 70 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1996 | 134 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1996 | 275 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1994 | 475 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1993 | 41 | 0.010 |
Why?
|
| Base Sequence | 1 | 1993 | 2317 | 0.000 |
Why?
|